The Icos Alumni: Where Are They Now?
Luke Timmerman11/18/09Comments (4)Follow @ldtimmerman
(Page 4 of 9)
—Kerry Fowler, principal, KFW Consulting
—Paul Fredlund, biotechnology consultant
—Steven Frey, Theraclone Sciences
—Mark Fromhold, vice president of manufacturing and process development, Koronis Pharmaceuticals
—Lyn Frumkin, biotechnology consultant
—Michael Gallatin, president, Calistoga Pharmaceuticals
—Christopher Gann, vice president, Starbucks
—Bob Garcia Jr., senior research associate scientist, Genentech
—Leon Garcia-Martinez, associate director, Alder Biopharmaceuticals
—Jeff Gardin, IT director, CMC Icos
—Dean Gittleman, senior director of biometrics, Vertex Pharmaceuticals [Added 12/30/09]
—Phyllis Goldman, senior program manager, Merck
—David Goodkin, independent biotechnology professional
—Kathy Goodman, executive assistant
—Rebecca Gottschalk, senior research associate, Trubion Pharmaceuticals
—Patrick Gray, chief scientific director, Accelerator
—Melanie Gray, medical student
—Jacinthe Guindon, director of clinical operations, Viventia Biotech
—Stephen Hadley, vice president of quality, CMC Icos
—Jim Halbrook, senior research scientist, Albany Molecular Research
—Kristi Hamilton, research associate III, Institute for Systems Biology
—Christine Hansen, senior research associate, Seattle Genetics
—Lori Hansen, director of project management, Seattle Genetics
—Kevin Harbol, senior group leader, Omeros
—Pat Hardwick, information technology support manager, College Success Foundation
—Justin Hare, in vivo toxicology study coordinator, Amgen
—Edith Harris, scientist, Mirina
—Nataly Hawthorn, biotechnology professional
—Joel Hayflick, former senior oncology early product development team leader, Genentech
—Allen Heck, director of operations, Northshore Sheet Metal
—Lee Hendrickson, owner, Side Street Photographics
—Christopher Henney, chairman of the board, Oncothyreon, director, AVI Biopharma
—Kelly Hensley, senior associate scientist, Amgen … Next Page »
Luke Timmerman is the National Biotech Editor of Xconomy, and the Editor of Xconomy Seattle. E-mail him at ltimmerman@xconomy.com or follow him on Twitter at twitter.com/ldtimmerman.
Johnny T. Stine
11/18/09 1:48 pm
I actually loved our logo – very simple, but it just looked like fun.
When George R. was recently asked by a reporter from an Everett newspaper about building Icos into a company like Amgen….he replied “…..why would I stop there?”. With a leader like that, like George, one who inspires with energetic goals such as that mentioned – we could’ve done it. We had the tools and the ability to do just that. We had great people who’ve all proven themselves in places before and afterward…….but imagine what we could’ve done behind the hopes of a great leader like George who set that tone….a CEO who knew all of our names, someone who would talk to you like you were a valued asset, a guy that empowered us via ownership. Imagine what we could’ve done…..because that’s all we’re left to do.
By the way- Luke – I prefer Icosanoids – a play on the word eicosanoid since we were primarily an inflammation company. :-)
Luke Timmerman
11/18/09 2:04 pm
Johnny—Unfortunately, I never really got to know George very well because he had already left Icos by the time I started covering the company in 2001. But I made a point of meeting him at his home once a couple years ago when I was based in San Francisco. He wasn’t in great health, but he was still sharp and very much curious about the latest happenings in biotech.
I haven’t heard the term Icosanoids from eicosanoid, but that made me laugh this morning. It sounds like something from Star Trek. Anybody know if this was also the inspiration for the term “Immunoids” for people who used to work at Immunex?
David Miller
11/23/09 2:54 pm
Nice work, Luke. Goes to prove that even though we might lose companies through acquisition we’d really rather keep, it’s not like everything connected with the company disappears. By my eye, the “loss” of Icos created at least a half-dozen new companies and significantly strengthened a dozen or more startups. A nice silver lining.
Abby Kliphardt
3/3/10 10:19 am
Nice article…good to see where my co-workers have ended. I loved my time at ICOS and will always lament the loss of a great company that was a real family….